Zion Labs T-5 ECA

Zion Labs T-5 (ECA Stack)

• Brand: Zion Labs
• Category: Thermogenic · High-stim ECA (Ephedrine + Caffeine + Aspirin)
• Content: 90 capsules
• Per Capsule (Label): Ephedrine 30 mg · Caffeine 250 mg · Aspirin 150 mg
• Manufactured in: Cyprus
• Research Notice: For laboratory and analytical use only. Not for human or veterinary consumption.

Product Overview

T-5 by Zion Labs is a classical ECA stack combining

ephedrine, caffeine, and aspirin into a single high-stimulus capsule aimed at

research on:

• thermogenesis and metabolic stimulation
• adrenergic signaling and norepinephrine-driven pathways
• energy, focus, and pre-exercise arousal
• body-mass and calorie-restriction models
• stimulant synergy (ephedrine + caffeine)

ECA protocols are extensively referenced in older metabolic and obesity studies, making T-5 a structured stimulant model for comparative research.

Key Research Highlights

Ephedrine (30 mg):

Indirect sympathomimetic that increases norepinephrine release and stimulates -adrenergic receptors promotes lipolysis, thermogenesis, and increased energy expenditure.

Studies consistently show enhanced thermogenesis when paired with caffeine.

Caffeine (250 mg):

Adenosine A1/A2A antagonist heightened CNS arousal, reduced perceived effort, improved alertness, and potential metabolic increases.

Commonly researched in performance and weight-management contexts.

Aspirin (150 mg):

Included historically in ECA protocols; proposed to attenuate prostaglandin-mediated feedback. Evidence suggests limited enhancement beyond EC alone but remains part of traditional triads.

Mechanism of Action (Simplified)

• Ephedrine: Increases synaptic NE -adrenergic activation lipolysis + thermogenic output.
• Caffeine: Blocks adenosine receptors boosts alertness, metabolic activity, and enhances ephedrine response.
• Aspirin: Historically added to prolong thermogenic signaling (evidence variable).

Technical Specification Table

Field

Data

Per-Capsule Actives

Ephedrine 30 mg · Caffeine 250 mg · Aspirin 150 mg

Pharmacology

• Ephedrine: -adrenergic stimulant
• Caffeine: adenosine A1/A2A antagonist
• Aspirin: COX inhibitor (ECA protocol component)

Evidence Snapshot (ECA)

Clinical studies show increased thermogenesis and modest weight reduction vs placebo; strong regulatory restrictions due to cardiovascular/CNS risks.

Doping Status

Ephedrine prohibited in-competition above 10 µg/mL urine.

Caffeine not prohibited, but monitored in some sports.

Regulatory Note

Ephedrine-alkaloid supplements banned in U.S. (FDA); restricted across many jurisdictions.

Origin

Cyprus

Research Background

• ECA literature: Studies indicate increased metabolic rate and short-term body-mass reduction via -adrenergic stimulation and caffeine synergy.
• Caffeine potentiation: Caffeine enhances ephedrine’s thermogenic effect in multiple controlled papers.
• Safety drives regulation: Cardiovascular and CNS risks prompted global regulatory tightening.

Potential Side Effects (Class-Based Literature)

• Elevated blood pressure, tachycardia, palpitations
• Insomnia, anxiety, tremors, agitation
• Headache, nausea, GI discomfort
• Rare severe events: arrhythmia, stroke, myocardial infarction
• Risk increases when combined with other stimulants or MAO inhibitors

Compliance & Doping Status

Sport:

Ephedrine is prohibited in-competition above 10 µg/mL urine under WADA rules.

Athletes should avoid use and consult federation guidelines.

Regulation:

Ephedrine-containing dietary supplements are illegal in the U.S. and restricted in many jurisdictions. Importation or sale may be blocked by authorities.

Research-only:

Not a supplement or medication. No human consumption implied. Supplied for analytical, forensic, and laboratory work only.

Important Notice

For research use only. Not a dietary supplement, not a medicine, and not for performance enhancement.

Users must follow local laws, laboratory safety policies, and anti-doping rules.